Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK: Top investment bank has its say after drug giant's better-than-expected results
06:49am, Thursday, 02'nd Feb 2023
The current year looks to be ‘shaping up nicely' for GSK PLC (LSE:GSK, NYSE:GSK), according to Barclays Capital in the wake of Wednesday's fourth-quarter and full-year results. It did, however, say
GSK chronic kidney disease drug receives green light
05:58am, Thursday, 02'nd Feb 2023
The US Food and Drug Administration (FDA) has given the green light to Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of adults with chronic kidne
GSK Shows That The COVID-19 Show Is Passing
05:10pm, Wednesday, 01'st Feb 2023
As predicted by some epidemiologists at the onset of the pandemic, COVID-19 would become an endemic flu-like condition not warranting mandated concern. The growth in sales of COVID-19 therapies and di
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
12:02pm, Wednesday, 01'st Feb 2023
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
GSK plc (GSK) Q4 2022 Earnings Call Transcript
10:25am, Wednesday, 01'st Feb 2023
GSK plc (NYSE:GSK ) Q4 2022 Earnings Conference Call February 1, 2023 6:00 AM ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scie
GSK CEO Emma Walmsley on beating Q4 earnings
09:29am, Wednesday, 01'st Feb 2023
GlaxoSmithKline CEO Emma Walmsley joins 'Squawk Box' to discuss company's growth drivers this quarter, the company's Shingles vaccine and the medical giant's RSV vaccine.
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
09:16am, Wednesday, 01'st Feb 2023
GSK stock and NVO stock rose Wednesday on fourth-quarter beats, but Novartis stock fell on lighter-than-expected sales despite strong profit. The post Pharma Giants GSK, Novo Nordisk Beat Expectations
GSK bidding to be first with an RSV vaccine. Here's our 2-minute guide
09:16am, Wednesday, 01'st Feb 2023
We heard earlier on Wednesday that GSK PLC (LSE:GSK, NYSE:GSK) could be the first to the market with a drug for RSV, a cold-like condition that can be deadly. Here we take a look at what exactly is an
GSK (GSK) Q4 Earnings and Revenues Top Estimates
08:17am, Wednesday, 01'st Feb 2023
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK 'beats the Street'; enters '23 with strong momentum
02:44am, Wednesday, 01'st Feb 2023
GSK PLC (LSE:GSK, NYSE:GSK) has reported better-than-expected fourth-quarter results, largely due to strong sales of its popular shingles vaccine, Shingrix. The pharma giant, which spun out its Haleon
GSK posts higher sales and profit of $1.85 billion, lifted by specialty medicines and vaccines businesses
02:43am, Wednesday, 01'st Feb 2023
GSK PLC on Wednesday posted rising earnings and sales for the fourth quarter, which the company said were boosted by its specialty medicines and vaccines businesses.
GSK Q4 results beat expectations, helped by Shingrix
02:20am, Wednesday, 01'st Feb 2023
GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix.
GSK, Vodafone and Entain all updating, Wednesday's agenda
09:01am, Tuesday, 31'st Jan 2023
Kicking off the new month are a trio of intriguing London blue-chips, with the US Fed decision to grab all the headlines later. In London, heavyweight pharma contender GSK PLC (LSE:GSK, NYSE:GSK),
GSK: A Defensive With A Healthy Dividend Yield
08:00pm, Monday, 30'th Jan 2023
Pharmaceuticals company GSK has seen a nice run up in price in Q4 2022. But with a rotation in favour of consumer stocks, can this continue? Its upcoming results could be an indicator. With earnings g
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
09:56am, Monday, 30'th Jan 2023
The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday. The post The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs
